Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. (NASDAQ: MDXG) is a Florida-incorporated regenerative medicine and advanced wound care company that files regular reports and disclosures with the U.S. Securities and Exchange Commission. On this page, investors can review MiMedx SEC filings, including current reports on Form 8-K that detail quarterly earnings announcements, investor presentations, and shareholder meeting results, as well as other periodic reports available through EDGAR.
Recent Form 8-K filings show MiMedx reporting quarterly financial results and furnishing earnings press releases and slide presentations under Items 2.02 and 7.01. Another 8-K describes the outcomes of the company’s annual meeting of shareholders, including director elections, advisory votes on executive compensation, ratification of the independent registered public accounting firm, and approval of amendments to the equity and cash incentive plan. These documents provide insight into MiMedx’s financial condition, governance, and shareholder decisions.
For a fuller picture of MiMedx’s business, risks, and accounting policies, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible via the SEC’s EDGAR system. Those filings contain detailed discussions of the company’s advanced wound care and placental tissue–based product portfolio, risk factors, legal and regulatory matters, and management’s analysis of operations.
Stock Titan’s SEC filings page is designed to surface MiMedx filings as they are posted to EDGAR and to pair them with AI-generated summaries. These summaries can help explain complex sections of lengthy documents, highlight key items such as revenue trends, legal disclosures, or shareholder votes, and make it easier to locate information on topics like reimbursement risk, litigation with former employees, or regulatory interactions. Users can also review insider and governance-related disclosures, such as say-on-pay frequency decisions, as they appear in MiMedx’s filed materials.
MiMedx Group, Inc. reported record fourth-quarter and full-year 2025 results, with net sales of $118.1 million for the quarter, up 27% year-over-year, and $418.6 million for the year, up 20%. Growth was driven by Wound sales rising 28% in Q4 and Surgical sales up 25%, supported by new products like EPIXPRESS, EMERGE and strong AMNIOFIX and AMNIOEFFECT performance.
Fourth-quarter GAAP net income was $15.2 million, or $0.10 per diluted share, while Adjusted EBITDA reached $29.4 million, a 24.9% margin. For 2025, GAAP net income was $48.6 million and Adjusted EBITDA was $105.7 million, representing a 25.3% margin. Gross margin stayed above 82% on a GAAP basis and 85% on an adjusted basis for the year.
Cash and cash equivalents were $166.1 million at December 31, 2025, with net cash of $148 million after debt, up $63 million year-over-year. The board authorized a share repurchase program of up to $100 million over two years. For 2026, MiMedx estimates net sales of $340–360 million and expects an Adjusted EBITDA margin in the mid-to-high teens, reflecting anticipated Medicare reimbursement changes that may pressure near-term Wound revenue.
MiMedx Group, Inc. files its annual report describing a wound care and surgical biologics business built around placental allografts and a growing portfolio of animal‑derived and distributed products. The company focuses on chronic and hard‑to‑heal wounds and increasing use of its tissues in surgical procedures.
MiMedx highlights its PURION processing technology, extensive clinical evidence for products like EPIFIX, and expansion into xenografts with FDA 510(k)‑cleared HELIOGEN. It is also growing internationally, particularly in Japan, where EPIFIX is approved and reimbursed as a Class IV medical device.
The report notes significant Medicare reimbursement reforms for skin substitutes effective in 2026, which shift payment to a flat rate per square centimeter, creating potential pressure on industry economics. As of June 30, 2025, non‑affiliate market value was about $719 million, and 148,566,586 shares were outstanding as of February 19, 2026.
MiMedx Group Chief Operating Officer Ricci S. Whitlow reported a tax-related share disposition. On the vesting of restricted stock, 61,961 shares of common stock were withheld by the company to satisfy tax withholding requirements at $5.12 per share. After this transaction, Whitlow directly owns 388,662 shares of MiMedx Group common stock, which includes 1,675 shares previously acquired through the company’s Employee Stock Purchase Plan.
MiMedx Group, Inc. has a new ownership update from Trigran-affiliated investors. An amended Schedule 13G shows Trigran Investments, Inc. and related individuals collectively reporting beneficial ownership of 6,163,384 shares of MiMedx common stock, representing 4.2% of the outstanding class as of the reported date.
The group reports no sole voting or dispositive power, with shared voting power over 5,688,192 shares and shared dispositive power over 6,163,384 shares. The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MiMedx.
MiMedx Group, Inc. filed a Form 8-K to share that it updated its investor presentation on January 12, 2026, furnishing the slide deck as Exhibit 99.1 under Regulation FD. The materials include forward-looking statements about future sales and sales growth, 2026 and longer-term financial goals such as net sales, Adjusted EBITDA, margins, corporate expenses and cash, as well as expectations for the placental tissue market, Medicare spending and growth across care settings. The company highlights numerous risks that could cause actual results to differ and notes it has no obligation to update these forward-looking statements after the date of the report.
MiMedx Group (MDXG) reported an insider transaction by its Chief Commercial Officer, Kimberly Maersk‑Moller. On 11/06/2025, she sold 58,300 shares of common stock at a weighted average price of $7.4156 (Transaction Code: S). Following the sale, she beneficially owns 236,982 shares, held directly.
The price reflects multiple trades aggregated into a single weighted average. The reporting person has indicated she will provide full trade-by-trade pricing details upon request, as customary in such disclosures.
MiMedx Group (MDXG) furnished its quarterly results update. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02. The materials include an Earnings Press Release (Exhibit 99.1), an Earnings Call presentation (Exhibit 99.2), and an Investor Presentation (Exhibit 99.3).
Management scheduled a conference call and webcast on October 29, 2025, at 4:30 PM Eastern Daylight Time to discuss the quarter. The information in Items 2.02 and 7.01 is furnished, not filed, under the Exchange Act.
MiMedx Group (MDXG) reported a strong Q3 2025. Net sales rose to $113.7 million, up 35% year over year, driven by newer Wound products CELERA and EMERGE and broad-based Surgical strength. Wound sales reached $77.1 million (up 40%), and Surgical sales were $36.6 million (up 26%). Gross margin improved to 83.5% from 81.8% on favorable production variances and mix.
GAAP net income was $16.7 million with diluted EPS of $0.11, versus $0.05 a year ago, as operating income doubled to $22.2 million. Cash and equivalents increased to $142.1 million, supported by $49.0 million in operating cash flow year to date. The company ended the quarter with $18.3 million of term debt at a 6.5% rate and no borrowings on its revolver. Management highlighted potential reimbursement changes starting January 1, 2026, with CMS proposing a fixed price of $125.38 per square centimeter for skin substitutes across settings; final rules are expected this year.
MiMedx Group, Inc. (MDXG) disclosed that it will participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation. The presentation materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated by reference. The filing reiterates standard forward-looking statement language, noting that actual results may differ due to risks such as uncertain future sales, reimbursement dynamics, scientific outcomes, international commercialization challenges, and regulatory developments. The disclosure clarifies that the furnished information is not deemed "filed" for certain Exchange Act liabilities and is not automatically incorporated into other securities filings.